In contrast, bimagrumab, a fully human monoclonal antibody that inhibits activin type II receptors, results in significant fat mass loss, increased lean mass, and improved insulin sensitivity in people with obesity and T2D (107, 108). The gene discussed is INS; the disease is obesity disorder.